| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Goodrich Katherine serves as a Director at TARS. Across recent SEC filings that breaks down to 0 buys and 1 sell. Those positions are worth an estimated $139K at current prices.
The biggest single holding is TARS (~$139K) as Director. The recent filings there lean toward selling, a net 2,954 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Director | Sell | 2,954 | $62.08 | $183,384.32 | -57.0% | - | - |